RecruitingEarly Phase 1NCT05700916
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
Evaluation of Milk Polar Lipids on Lipoprotein Metabolism, Inflammation, and Gut Microbiota in Dyslipidemic Adults With Abdominal Obesity
Sponsor
University of Connecticut
Enrollment
130 participants
Start Date
Oct 20, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- LDL-C ≥ 130 mg/dL
- Waist circumference ≥ 88 cm for women, ≥ 102 cm for men
- Aged 18 to 70 years
Exclusion Criteria23
- Renal disease
- Liver disease
- Diabetes
- Heart disease
- Stroke
- Cancer
- Eating disorders
- Thyroid disease
- Gut-associated pathologies
- Autoimmune diseases
- Chronic inflammatory diseases
- Scleroderma
- Gallbladder disease
- Blood clotting disorders
- Intravenous drug use
- Fasting plasma/serum triglycerides \>500 mg/dL
- Fasting plasma/serum glucose \>126 mg/d
- Weight changes \>10% over last 4 weeks
- Oral antibiotics use up to 1 month prior to and during study
- Allergy or intolerance to milk products
- Taking lipid-lowering medications (e.g., statins, fibrates)
- Taking anti-inflammatory medications (e.g., corticosteroids)
- Taking medications which primarily affect blood clotting (e.g., warfarin).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMilk Polar Lipid-Rich Dairy Powder
Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
DIETARY_SUPPLEMENTDairy Powder
Effects of dairy control powder
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05700916
Related Trials
RemI for Post-Bariatric Surgery Weight Regain
NCT062929362 locations
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285119 locations
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459586 locations
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT0722568637 locations
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
NCT011434543 locations